Sign In
Buy TAK
$15.03
-0.150 (-0.99%)
At Close: Jun 03, 2026
All You Need to Know About Takeda Pharmaceutical Co. (TAK) Rating Upgrade to Strong Buy
01:00pm, Thursday, 25'th Apr 2024
Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
TAK or CTLT: Which Is the Better Value Stock Right Now?
12:45pm, Thursday, 25'th Apr 2024
Investors with an interest in Medical - Drugs stocks have likely encountered both Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks presents investors with the better
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
10:46am, Thursday, 25'th Apr 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
New Strong Buy Stocks for April 25th
07:56am, Thursday, 25'th Apr 2024
TAK, TXO, PEPG, ERO and RMNI have been added to the Zacks Rank #1 (Strong Buy) List on April 25, 2024.
Best Value Stocks to Buy for April 25th
07:16am, Thursday, 25'th Apr 2024
RMNI, TAK and ASBFY made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 25, 2024.
Best Income Stocks to Buy for April 25th
05:40am, Thursday, 25'th Apr 2024
CIB, TAK and ASBFY made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 25, 2024.
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
07:00am, Tuesday, 23'rd Apr 2024
SAVITRI™ Study Met Primary Endpoint with Statistically Significant Reduction in Montgomery Åsberg Depression Rating Scale ( MADRS) Total Score at Day 28 Met Key Secondary Endpoints, Including Stati
TOKYO , April 22, 2024 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK, President and CEO; Christophe Weber, "Takeda"), Astellas Pharma Inc. (TSE: 4503, President and CEO: N
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) adm
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the selection of eight new U.S. non-profit organizations as grant recipients, as part of its $14.6 million commitment to i
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
08:53am, Wednesday, 27'th Mar 2024
Takeda's 'In Their Shoes' initiative illuminates the daily struggles of IBD patients in the UAE, fostering empathy and understanding among participants. DUBAI, UAE, March 27, 2024 /PRNewswire/ --
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
07:07pm, Tuesday, 26'th Mar 2024
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors
2 More Potential Biotech Buyout Targets
01:07pm, Monday, 25'th Mar 2024
M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related produ
Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032
05:34pm, Thursday, 14'th Mar 2024
Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation th
Takeda Pharmaceutical Co. (TAK) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Monday, 11'th Mar 2024
Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
